Clostridium News and Research

RSS

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Clinical trial to test whether fecal transplantation is effective in treating relapsing C. difficile

For patients with Clostridium difficile (C. difficile), a persistent and potentially deadly bacterial illness, severe diarrhea, abdominal pain, nausea and vomiting are an everyday event. This particularly virulent infection is prone to recurrence, even after multiple courses of expensive antibiotics, and treatment options are limited for patients who continually relapse or develop antibiotic resistance.

22 Aug 2012

Wound dressing containing ionic silver capable of killing multidrug-resistant organisms

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of multidrug-resistant organisms (MDROs), commonly referred to as 'superbugs.' The study results were published in the August issue of the International Wound Journal.

13 Aug 2012

‘Green’ disinfectant shows promise against hospital-acquired infections

Research shows that the polyhexamethylene-guanidine hydrochloride-based disinfectant Akwaton effectively destroys Bacillus subtilis spores even at low concentrations.

8 Aug 2012

Aquapharm discovers new antibiotic compound against multi-drug resistant bacteria

A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.

6 Aug 2012

Cubist second quarter total net revenues increase 30% to $230.6M

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2012.

20 Jul 2012

Sandia researchers develop SpinDx medical diagnostic tool

Researchers at Sandia National Laboratories have developed a lab-on-a-disk platform that they believe will be faster, less expensive and more versatile than similar medical diagnostic tools.

14 Jul 2012

Cubist initiates CB-315 Phase 3 trial for Clostridium difficile-associated diarrhea

Cubist Pharmaceuticals, Inc. today announced the initiation of its pivotal Phase 3 studies evaluating the efficacy and safety of CB-315 in patients with Clostridium difficile-associated diarrhea, or CDAD, with enrollment of a patient in the first of two planned identical global trials.

13 Jul 2012

Health Canada approves XIAFLEX for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Canada Inc. announced today that Auxilium was granted a Notice of Compliance (approval) by Health Canada for XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, first-in-class biologic for the treatment of Dupuytren's contracture in adults with a palpable cord in Canada.

9 Jul 2012

BioSpecifics commences XIAFLEX Phase II trial in human lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that it has initiated its Phase II trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of human lipoma.

27 Jun 2012

Survey of home healthcare practices related to infection control

A healthy boy was infected with antibiotic-resistant bacterium that was traced to his mother's nurse's bag left in the family's car after his mother's home healthcare visit to a patient with the same infection. Although the boy's infection and the patient's infection were never DNA tested, the coincidence was remarkable.

26 Jun 2012

MountainView Hospital first in Nevada to use Xenex’s room disinfection device

In an ongoing effort to improve patient safety, MountainView Hospital today announced it is the first hospital in Nevada to use Xenex Healthcare Services' innovative germ-zapping room disinfection technology to keep patients even safer from infections.

21 Jun 2012

Novel strategy for neutralizing unwanted molecules and clearing them from the body

Researchers have unveiled a novel strategy for neutralizing unwanted molecules and clearing them from the body.

18 Jun 2012

Scientists image structure of bacterium protein coat

Bacteria are omnipresent - in the water, the air and the soil, as well as in plants, animals and even people. We tend to think of bacteria as pathogenic, causing disease. We associate them with intestinal upsets and throat infections, pneumonia and blood poisoning.

11 Jun 2012

Hospira releases enhancement to TheraDoc clinical surveillance system

Hospira, the world's leading provider of injectable drugs and infusion technologies, today released an important enhancement to its TheraDoc clinical surveillance system designed to support hospital antimicrobial stewardship efforts, with the goal of helping to improve patient outcomes, reduce antimicrobial resistant infections and reduce costs.

11 Jun 2012

BioMed Protect’s Sanotracin RTU rapidly and effectively kills C. difficile within 3 minutes

In the United States Clostridium difficile or "C. difficile" is now recognized as one of the most dangerous and fastest growing Healthcare Acquired Infections (HAIs) in existence. Now surpassing even Staphylococcus aureus (MRSA), C. difficile infections tripled between 2000 and 2005.

6 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

UV disinfection may reduce CDI in hospitals and LTCFs

In a recently published article, "Decontamination with Ultraviolet Radiation to Prevent Recurrent Clostridium difficile Infection in 2 Roommates in a Long-Term Care Facility" (Infection Control and Hospital Epidemiology, 05/2012), researchers shared the results of a trial that used Tru-D SmartUVC to prevent coincident recurrent CDI episodes in roommates in a Long-Term Care Facility (LTCF).

2 Jun 2012

C. difficile infection on the rise

A study presented by Mayo Clinic researchers during Digestive Disease Week 2012 provides clear evidence that the number of people contracting the hard-to-control and treat bacterial infection Clostridium difficile (C. difficile or C. diff) is increasing, and that the infection is commonly contracted outside of the hospital.

22 May 2012